Absence of Sustained Hyperlactatemia in HIV-Infected Patients with Risk Factors for Mitochondrial Toxicity

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 3, 2004, Pages 274-278

  Wohl, David A ^a,n   Pilcher, Christopher D ^a   Evans, Scott ^b   Revuelta, Manuel ^c   McComsey, Grace ^d   Yang, Yijun ^b   Zackin, Robert ^b   Alston, Beverly ^e   Welch, Stacey ^f   Basar, Michael ^g   Kashuba, Angela ^h   Kondo, Pualani ⁱ   Martinez, Ana ^e   Giardini, Jeffrey ^g   Quinn, Joseph ^j   Littles, Melvin ^k   Wingfield, Harry ^l   Koletar, Susan L ^m  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ UNIVERSITY OF HAWAII   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ NONE   (United States)

more..

Author keywords

Hyperlactatemia; Lactate; Mitochondrial toxicity; Nucleosides analogues

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LACTIC ACID; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; MULTICENTER STUDY; NAUSEA; NEUROPATHY; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; LACTATES; MALE; METABOLIC DISEASES; MITOCHONDRIA; PREVALENCE; RISK FACTORS; VITAMIN B COMPLEX;

EID: 10744229059     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200403010-00008     Document Type: Article

References (28)

1. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(Suppl):F25-F32.
2. Mokrzycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis. 2000;30:198-200.
3. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-166.
4. Acosta BS, Grimsley EW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South Med. J. 1999;92:421-423.
5. Gérard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emergency complication of antiretroviral therapy. AIDS. 2000;14:2723-2730.
6. Vrovenraets SME, Treskes M, Regez RM, et al. Hyperlactatemia in HIV-infected patients: the role of NRTI treatment [abstract 625]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001.
7. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 2001;15:717-723.
8. Bissuel F, Bruncel F, Habersetzer F, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med. 1994;235:367-371.
9. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 1999;30:156-160.
10. Allaouchiche B, Duflo F, Cotte L, et al. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy [letter]. J Antimicrob Chemother. 1999;44:137-138.
11. Sundar K, Suarez M, Banogon PE, et al. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med. 1997;25:1425-1430.
12. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med. 2000;133:192-196.
13. Tanaka K, Fukahori S, Jojima H, et al. Fatal lactic acidosis in a patient with acquired immunodeficiency syndrome treated with stavudine, lamivudine and indinavir. Kansenshogaku Zasshi. 1999;73:1232-1235.
14. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001;33:1931-1937.
15. Hocqueloux L, Alberti C, Feugeas J, et al. Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV Med. 2003;4:18-23.
16. Harris M, Chan KJ, Tesiorowski A, et al. Random venous lactate levels among HIV-positive patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:448-450.
17. McComsey GA, Yau L, Southwell H, et al. Elevated lactate levels are uncommon, even in heavily pretreated HIV-infected subjects [abstract T-710] Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002.
18. Gallagher EJ, Rodriguez K, Touger M. Agreement between peripheral venous and arterial lactate levels. Ann Emerg Med. 1997;29:479-483.
19. Brew B, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy [abstract 9]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001.
20. Verma A, Schein RMH, Jayaweera DT, et al. Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy. Neurology. 1999;53:1365-1367.
21. ter Hofstede HJM, de Marie S, Foudraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000;11:611-616.
22. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-846.
23. Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis. 2001;33:1914-1921.
24. Carr A, Miller J, Eisman JA, et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703-709.
25. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect. 2002;78:58-59.
26. Boxwell DE, Styrt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors [abstract 1284]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999.
27. Bristol-Myers Squibb Company. Healthcare provider important drug warning letter. January 5, 2001.
28. AIDS Clinical Trials Group (ACTG) Metabolic Complications Guides. Available at: http://aactg.s-3.com/metabolic/lactic.pdf.